Role of urotensin II in atherosclerotic cardiovascular diseases

Cardiovascular Revascularization Medicine

Volumn 9, Issue 3, 2008, Pages 166-178

  Pakala, Rajbabu ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Hypertension; Urotensin II

Indexed keywords

(4 CHLOROPHENYL)ALANYLCYSTEINYL (3 PYRIDYLALANYL) TRYPTOPHYLLYSYLVALYLCYSTEINYL (4 CHLOROPHENYL)ALANINAMIDE; (BETA2 NAPHTHYL)ALANYL [(CYSTEINYLTYROSYLTRYPTOPHYLORNITHYLVALYLCYSTEINYL] 2 (BETA2 NAPHTHYL)ALANINAMIDE; (FLUORO)PHENYLALANYLCYSTEINYL (3 PYRIDYLALANYLTRYPTOPHYLLYSYL) TERT LEUCYLCYSTEINYL 3 (2 NAPHTHYL)ALANINAMIDE; 1 [2 (4 BENZYL 4 HYDROXYPIPERIDIN 1 YL)ETHYL] 3 (2 METHYLQUINOLIN 4 YL)UREA SULFATE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACT 058362; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PALOSURAN; PRL 2903; PROTEIN KINASE INHIBITOR; SB 710411; SOMATOSTATIN DERIVATIVE; UROTENSIN II; UROTENSIN II RECEPTOR; UROTENSIN II RECEPTOR AGONIST; UROTENSIN II RECEPTOR ANTAGONIST; WORTMANNIN;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY WEIGHT; CAROTID ARTERY DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY FAILURE; LIGAND BINDING; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASOCONSTRICTION;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; SEVERITY OF ILLNESS INDEX; UROTENSINS; VASOCONSTRICTION;

EID: 46149099548     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2008.02.001     Document Type: Article

References (125)

1. Colton J., Yano K., Waugh D., and Hazon N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool 275 (1996) 226-238
2. Douglas S., Sulpizio A., Piercy V., Saraju H., Ames R., Aiyar N., Ohlstein E., and Willette R. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
3. Guerrini R., Camarda V., Marzola E., Arduin M., Calo G., Spagnol M., Rizzi A., Salvadori S., and Regoli D. Structure-activity relationship study on human urotensin II. J Pept Sci 11 (2005) 85-90
4. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J., Conlon J., Bern H., and Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
5. Russell F., Kearns P., Toth I., and Molenaar P. Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther 310 (2004) 209-214
6. Ames R., Sarau H., Chambers J., Willette R., Aiyar N., Romanic, Louden C., Foley J., Sauermelch C., Coatney R., Ao Z., Disa J., Holmes S., Stadel J., Martin J., Liu W., Glover G., Wilson S., McNulty D., Ellis C., Elshourbagy N., Shabon U., Trill J., Hay D., Ohlstein E., Bergsma D., and Douglas S. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
7. Douglas S., and Ohlstein E. Urotensin receptors. In: Girdlestone D. (Ed). The IUPHAR Compendium of Receptor Characterization and Classification (2000), IUPHAR Media, London 365-372
8. Elshourbagy N., Douglas S., Shabon U., Harrison S., Duddy G., Sechler J., Ao Z., Maleeff B., Naselsky D., Disa J., and Aiyar N. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 136 (2002) 9-22
9. Suzuki S., Wenyi Z., Hirai M., Hinokio Y., Suzuki C., Yamada T., Yoshizumi S., Suzuki M., Tanizawa Y., Matsutani A., and Oka Y. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 25 (2004) 1803-1808
10. Protopopov A., Kashuba V., Podowski R., Gizatullin R., Sonnhammer E., Wahlestedt C., and Zabarovsky E. Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. Cytogenet Cell Genet 88 (2000) 312-313
11. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., Kitada C., Miyajima N., Suzuki N., Mori M., and Fujino M. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
12. Mori M., and Fujino M. Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain. Peptides 25 (2004) 1815-1818
13. Russel F., Molenaar P., and O'Brien D. Cardio-stimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 (2001) 5-9
14. Bottrill F., Douglas S., Hiley C., and White R. Human urotensin-II is an endothelium-dependent vasodilator small arteries. Br J Pharmacol 130 (2000) 1865-1870
15. Maguire J., Kuc R., and Davenport A. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131 (2000) 441-446
16. Behm D., Harrison S., Ao Z., Maniscalco K., Pickering S., Grau E., Woods T., Coatney R., Doe C., Willette R., Johns D., and Douglas S. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 139 (2003) 464-472
17. Camarda V., Rizzi A., Calo G., Gendron G., Perron S., Kostenis E., Zamboni P., Mascoli F., and Regoli D. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch. Pharmacol 365 (2002) 141-149
18. Bohm F., and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135 (2002) 25-27
19. Wilkinson I., Affolter J., de Haas S., Pellegrini M., Boyd J., Winter M., Balment R., and Webb D. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 53 (2002) 341-347
20. Affolter J., Newby D., Wilkinson I., Winter M., Balment R., and Webb D. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 54 (2002) 617-621
21. Gardiner S., March J., Kemp P., Davenport A., and Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132 (2001) 1625-1629
22. Lin Y., Tsuchihashi T., Matsumura K., Abe I., and Iida M. Central cardiovascular action of urotensin II in conscious rats. J Hypertens 21 (2003) 159-165
23. Ishihata A., Sakai M., and Katano Y. Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide. Peptides 27 (2006) 80-86
24. Lim M., Honisett S., Sparkes C., Komesaroff P., Kompa A., and Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 109 (2004) 1212-1214
25. Sondermeijer B., Kompa A., Komesaroff P., and Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 18 (2005) 1195-1199
26. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol 91 (1987) 205-212
27. Gray G., Jones M., and Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 69 (2001) 175-180
28. Katano Y., Ishihata A., Aita T., Ogaki T., and Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 402 (2000) R5-R7
29. Lacza Z., and Busija D. Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci 78 (2006) 2763-2766
30. Zhang A., Chen Y., Zhang D., Yi F., Qi J., Andrade-Gordon P., de Garavilla L., Li P., and Zou A. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 285 (2003) F792-F798
31. Douglas S., Ashton D., Sauermelch C., Coatney R., Ohlstein D., Ruffolo M., Ohlstein E., Aiyar N., and Willette R. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 36 (2000) S163-S166
32. Hillier C., Berry C., Petrie M., O'Dwyer P., Hamilton C., Brown A., and McMurray J. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103 (2001) 1378-1381
33. Stirrat A., Gallagher M., Douglas S., Ohlstein E., Berry C., Kirk A., Richardson M., and MacLean M. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280 (2001) H925-H928
34. MacLean M., Alexander D., Stirrat A., Gallagher M., Douglas S., Ohlstein E., Morecroft I., and Polland K. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130 (2000) 201-204
35. Ishihata A., Ogaki T., Aita T., and Katano Y. Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 523 (2005) 119-126
36. Behm D., Doe C., Johns D., Maniscalco K., Stankus G., Wibberley A., Willette R., and Douglas S. Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 274-280
37. Lin Y., Tsuchihashi T., Matsumura K., Fukuhara M., Ohya Y., Fujii K., and Iida M. Central cardiovascular action of urotensin II in spontaneously hypertensive rats. Hypertens Res 26 (2003) 839-845
38. Watson, Lambert G., Smith K., and May C. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
39. Song W., Abdel-Razik A., Lu W., Ao Z., Johns D., Douglas S., Balment R., and Ashton D. Urotensin II and renal function in the rat. Kidney Int 69 (2006) 1360-13688
40. Cheung B., Leung R., Man Y., and Wong L. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22 (2004) 1341-1344
41. Thompson J., Watt P., Sanghavi S., Strupish J., and Lambert D. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg 97 (2003) 1501-1503
42. Rdzanek A., Filipiak K., Karpiński G., Grabowski M., and Opolski G. Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension. Int J Cardiol 110 (2006) 175-178
43. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., and Hirata Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 19 (2001) 2185-2190
44. Yi L., Gu Y., Wang X., An L., Xie X., Shao W., Ma L., Fang J., An Y., Wang F., and Zhang D. Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. J Int Med Res 34 (2006) 272-283
45. Ong K., Wong L., Man Y., Leung R., Song Y., Lam K., and Cheung B. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 27 (2006) 1659-1667
46. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 104 (2003) 1-5
47. Sheridan M., Plisetskaya E., Bern H., and Gorbman A. Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. en Comp Endocrinol 66 (1987) 405-414
48. Sauzeau V., Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 (2001) 1102-1104
49. Silvestre R., Egido E., Hernández R., Leprince J., Chatenet D., Tollemer H., Chartrel N., Vaudry H., and Marco J. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 151 (2004) 803-809
50. Silvestre R., Rodriguez-Gallardo J., Egido E., and Marco J. Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas. Horm Metab Res 33 (2001) 379-381
51. Du W., Sun H., Wang H., Qiang B., Shen Y., Yao Z., Gu J., Xiong M., Huang W., Chen Z., Zuo J., Hua X., Gao W., Sun Q., and Fang F. Confirmation of susceptibility gene loci on chromosome 1 in northern China Han families with type 2 diabetes. Chin Med J 114 (2001) 876-878
52. Mori Y., Otabe S., Dina C., Yasuda K., Populaire C., Lecoeur C., Vatin V., Durand E., Hara K., Okada T., Tobe K., Boutin P., Kadowaki T., and Froguel P. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate loci on 7p and 11p. Diabetes 51 (2002) 1247-1255
53. Sun H., Du W., Zuo J., Wu G., Shi G., Shen Y., Qiang B., Yao Z., Hang J., Wang H., Huang W., Chen Z., and Fang F. The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24 (2002) 223-227
54. Zhu F., Ji L., and Luo B. The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population. Zhonghua Yi Xue Za Zhi 82 (2002) 1473-1475
55. Wenyi Z., Suzuki S., Hirai M., Hinokio Y., Tanizawa Y., Matsutani A., Satoh J., and Oka Y. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 46 (2003) 972-976
56. Charles C., Rademaker M., Richards A., and Yandle T. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides 26 (2005) 2211-2214
57. Gartlon J., Parker F., Harrison D., Douglas S., Ashmeade T., Riley G., Hughes Z., Taylor S., Munton R., Hagan J., Hunter J., and Jones D. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology (Berl) 155 (2001) 426-433
58. Williams G., Bing C., Cai X., Harrold J., King P., and Liu X. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 74 (2001) 683-701
59. Do-Rego J., Chatenet D., Orta M., Naudin B., Le Cudennec C., Leprince J., Scalbert E., Vaudry H., and Costentin J. Behavioral effects of urotensin-II centrally administered in mice. Psychopharmacology (Berl) 183 (2005) 103-117
60. Johns D., Ao Z., Naselsky D., Herold C., Maniscalco K., Sarov-Blat L., Steplewski K., Aiyar N., and Douglas S. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 238-250
61. Birker-Robaczewska M., Boukhadra C., Studer R., Mueller C., Binkert C., and Nayler O. The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res 23 (2003) 289-305
62. Djordjevic T., BelAiba R., Bonello S., Pfeilschifter J., Hess J., and Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25 (2005) 519-525
63. Mallamaci F., Cutrupi S., Pizzini P., Tripepi G., and Zoccali C. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 19 (2006) 505-510
64. Dai H., Kang W., Wang X., Yu X., Li Z., Tang M., Xu D., Li C., Zhang Y., and Ge Z. The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul Pept 140 (2007) 88-93
65. Hassan G., Douglas S., Ohlstein E., and Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 26 (2005) 2464-2472
66. Bousette N., Patel L., Douglas S., Ohlstein E., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 (2004) 117-123
67. Suguro T., Watanabe T., Ban Y., Kodate S., Misaki A., Hirano T., Miyazaki A., and Adachi M. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20 (2007) 211-217
68. Wang Z., Shi L., Xiong Z., Zhang L., Meng L., Bu D., Tang C., and Ding W. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides 27 (2006) 858-863
69. Rakowski E., Hassan G., Dhanak D., Ohlstein E., Douglas S., and Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol 39 (2005) 785-791
70. Watanabe T., Takahashi K., Kanome T., Hongo S., Miyazaki A., Koba S., Katagiri T., Pakala R., and Benedict C. Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 29 (2006) 821-831
71. Watanabe T., Pakala R., Katagiri T., and Benedict C. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 (2001) 16-18
72. Watanabe T., Pakala R., Katagiri T., and Benedict C. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 19 (2001) 2191-2196
73. Shi L., Ding W., Li D., Wang Z., Jiang H., Zhang J., and Tang C. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188 (2006) 260-264
74. Watanabe T., Suguro T., Kanome T., Sakamoto Y., Kodate S., Hagiwara T., Hongo S., Hirano T., Adachi M., and Miyazaki A. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46 (2005) 738-744
75. Joyal D., Huynh T., Aiyar N., Guida B., Douglas S., and Giaid A. Urotensin-II levels in acute coronary syndromes. Int J Cardiol 108 (2006) 31-35
76. Gruson D., Rousseau M., Ahn S., van Linden F., and Ketelslegers J. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 27 (2006) 1527-1531
77. Ng L., Loke I., O'Brien R., Squire I., and Davies J. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
78. Richards, Nicholls M., Lainchbury J., Fisher S., and Yandle T. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
79. Russell F., Meyers D., Galbraith A., Bett N., Toth I., Kearns P., and Molenaar P. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H1576-H1581
80. Heringlake M., Kox T., Uzun O., Will B., Bahlmann L., Klaus S., Eleftheriadis S., Armbruster F., Franz N., and Kraatz E. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121 (2004) 129-136
81. Russell F., Molenaar P., and O'Brien D. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 (2001) 5-9
82. Hunt S., Baker D., Chin M., Cinquegrani M., Feldman A., Francis G., Ganiats T., Goldstein S., Gregoratos G., Jessup M., Noble R., Packer M., Silver M., Stevenson L., Gibbons R., Antman E., Alpert J., Faxon D., Fuster V., Gregoratos G., Jacobs A., Hiratzka L., Russell R., and Smith S. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation 104 (2001) 2996-3007
83. Zou Y., Nagai R., and Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 508 (2001) 57-60
84. Tzanidis A., Hannan R., Thomas W., Onan D., Autelitano D., See F., Kelly D., Gilbert R., and Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
85. Onan D., Pipolo L., Yang E., Hannan R., and Thomas W. Urotensin-II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18 (2004) 2344-2354
86. Douglas S., Tayara L., Ohlstein E., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
87. Lapp H., Boerrigter G., Costello-Boerrigter L., Jaekel K., Scheffold T., Krakau I., Schramm M., Guelker H., and Stasch J. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
88. Zhou P., Wu S., Yu C., Wang H., Tang C., Lin L., and Yuan W. Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion. Sheng Li Xue Bao 55 (2003) 442-448
89. Russell F., and Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res 63 (2004) 673-681
90. Zhang Y., Li J., Cao J., Chen J., Yang J., Zhang Z., Du J., and Tang C. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 16 (2002) 64-68
91. Khan S., Bhandari S., Quinn P., Davies J., and Ng L. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 117 (2007) 323-328
92. Zoccali C., Mallamaci F., Tripepi G., Cutrupi S., Pizzini P., and Malatino L. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int 69 (2006) 1253-1258
93. Saetrum O., Nothacker H., Ehlert F., and Krause D. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 406 (2000) 265-271
94. Tasaki K., Hori M., Ozaki H., Karaki H., and Wakabayashi I. Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci 94 (2004) 376-383
95. Rossowski W., Cheng B., Taylor J., Datta R., and Coy D. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438 (2002) 159-170
96. Wang Y., Ding Y., Zhu Y., Shi Y., Yao T., and Zhu Y. Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am J Physiol Heart Circ Physiol 292 (2007) H348-H359
97. Matsusaka S., and Wakabayashi I. Enhancement of vascular smooth muscle cell migration by urotensin II. Naunyn Schmiedebergs Arch Pharmacol 3735 (2006) 381-386
98. Tamura K., Okazaki M., Tamura M., Isozumi K., Tasaki H., and Nakashima Y. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 72 (2003) 1049-1060
99. Itoh H., McMaster D., and Lederis K. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur J Pharmacol 149 (1988) 61-66
100. Coy D., Rossowski W., Cheng B., and Taylor J. Structural requirements at the N-terminus of urotensin II octapeptides. Peptides 23 (2002) 2259-2264
101. Flohr S., Kurz M., Kostenis E., Brkovich A., Fournier A., and Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45 (2002) 1799-1805
102. Grieco P., Carotenuto A., Patacchini R., Maggi C., Novellino E., and Rovero P. Design, synthesis, conformational analysis and biological studies of urotensin-II lactam analogues. Bioorg Med Chem 10 (2002) 3731-3739
103. Kinney W., Almond H., Qi J., Smith C., Santulli R., de Garavilla L., Andrade-Gordon P., Cho D., Everson A., Feinstein M., Leung P., and Maryanoff B. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl 41 (2002) 2940-2944
104. Grieco P., Carotenuto A., Campiglia P., Zampelli E., Patacchini R., Maggi C., Novellino E., and Rovero P. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J Med Chem 45 (2002) 4391-4394
105. Croston G., Olsson R., Currier E., Burstein E., Weiner D., Nash N., Severance D., Allenmark S., Thunberg L., Ma J., Mohell N., O'Dowd B., Brann M., and Hacksell U. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). J Med Chem 45 (2002) 4950-4953
106. Behm D., Herold C., Ohlstein E., Knight S., Dhanak D., and Douglas S. Pharmacological characterization of SB-710411 (Cpa-c[d-Cys-Pal-d-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 137 (2002) 449-458
107. Herold C., Behm D., Buckley P., Foley J., Wixted W., Sarau H., and Douglas S. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br J Pharmacol 139 (2003) 203-207
108. Dhanak D., and Knight S. Urotensin-II receptor antagonists (2001) WO/2001/0145694
109. Dhanak D., Knight S., Jim J., and Keenan R. Urotensin-II receptor antagonists (2001) WO/2001/45711
110. Tarui N., Santo T., Mori M., and Watanabe H. Vasoactive agents (2001) W/2001/66143]
111. Tarui N., Santo T., Watanabe H., Aso K., Miwa T., and Takekawa S. Biphenyl compound (2002) WO/2002/00606
112. Tarui N., Santo T., Watanabe K., Aso K., and Ishhara Y. GPR14 antagonist (2002) WO/2002/02530
113. Aissaoui H., Binkeret C., Clozel M., Mathys B., Mueller C., Nayler O., Scherz M., Velker J., and Weller T. Preparation of 1,2,3,4-tetrahydroisoquinolinyl ureas and related derivatives as urotensin II receptor antagonists (2002) WO/2002/76979
114. Dhanak D., Knight S., Jim J., and Keenan R. reparation of N-(2-quinolinyl)propane-1,3-diamines as urotensin-II receptor antagonists (2002) WO/2002/58702
115. Clozel M., Binkert C., Birker-Robaczewska M., Boukhadra C., Ding S., Fischli W., Hess P., Mathys B., Morrison K., Müller C., Müller C., Nayler O., Qiu C., Rey M., Scherz M., Velker J., Weller T., Xi J., and Ziltener P. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311 (2004) 204-212
116. Douglas S. Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?. Curr Opin Pharmacol 3 2 (2003) 159-167
117. Patacchini R., Santicioli P., Giuliani S., Grieco P., Novellino E., Rovero P., and Maggi C. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol. 140 (2003) 1155-1158
118. Douglas S., Dhanak D., and Johns D. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25 (2004) 76-85
119. Clozel M., Hess P., Qiu C., Ding S., and Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316 (2006) 1115-1121
120. Bousette N., Hu F., Ohlstein E., Dhanak D., Douglas S., and Giaid A. .Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 41 (2006) 285-295
121. Bousette N., Pottinger J., Ramli W., Ohlstein E., Dhanak D., Douglas S., and Giaid A. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27 (2006) 2919-2926
122. Bousette N., and Giaid A. Urotensin-II and cardiovascular diseases. Curr Hypertens Rep 8 (2006) 479-483
123. Sidharta P., Wagner F., Bohnemeier H., Jungnik A., Halabi A., Krähenbühl S., Chadha-Boreham H., and Dingemanse J. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 80 (2006) 246-256
124. Pakala R., Leborgne L., Cheneau E., Chen R., Yazdi H., Fournanadjiev J., Weber D., Hellinga D., Kolodgie F., Virmani R., and Waksman R. Radiation-induced atherosclerotic plaque progression in a hypercholesterolemic rabbit: a prospective vulnerable plaque model?. Cardiovasc Radiat Med. 4 (2003) 146-151
125. Pakala R., Dilcher C., Baffour R., Hellinga D., Seabron R., Joner M., Kolodgie F., Virman R., and Waksman R. Peroxisome proliferator-activated receptor g ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit. J Cardio Vasc Pharmacol 48 (2006) 299-305